MCRB

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Seres Therapeutics Inc revenue for the last quarter amounts to 351.00K USD, decreased % YoY.

Seres Therapeutics Inc. EPS for the last quarter amounts to 0.94 USD, decreased -91.92 % YoY.

Seres Therapeutics Inc (MCRB) has 103 emplpoyees as of January 10 2026.

Today MCRB has the market capitalization of 141.58M USD.